Following the FDA approval of Moderna COVID-19 vaccine (Spikevax) for individuals 18 years and older on 31JAN2022, ACIP met today to review the complete package of data submitted with the BLA on this vaccine. At the end of the first portion of the meeting, the ACIP took a vote on the following policy question: Should vaccination with the Moderna COVID-19 vaccine (Spikevax, 2-dose primary series) be recommended for persons 18 years of age and older?, There was a unanimous vote in favor.
To view the CDC ACIP Meeting Report from February 4th 2022, see below.
Loading...
Reload document 
Open in new tab 
